Market Intelligence for Hereditary Angioedema (HAE) Therapeutics, Diabetic Macular Edema (DME), and High-Purity Assay Reagents for Serine Protease Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KLKB1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Zymogen) | KLKB1 Recombinant Protein (Prekallikrein) High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. HEK293 Expressed for native glycosylation. |
View KLKB1 Products |
| Antigen (Active) | Activated KLKB1 (Factor XIIa processed) Enzymatically validated form for inhibitor screening. Theoretical MW verified. |
View KLKB1 Products |
| Gene Delivery | KLKB1 Lentivirus Particles Full-length ORF for stable cell line construction. High titer (>10^8 TU/ml). |
View KLKB1 Products |
| Benchmark Ab | Anti-KLKB1 (Lanadelumab Biosimilar Sequence) Recombinant human IgG1 positive control for binding/blocking assays. |
View KLKB1 Products |
| Validator | KLKB1 siRNA Set Gene-specific knockdown for assay specificity verification. |
View KLKB1 Products |
| Upstream Activator | F12 (Factor XII) Biological activator of KLKB1 zymogen. Required for activation assays. |
View F12 Products |
| Substrate | KNG1 (Kininogen) Natural substrate for functional cleavage assays. |
View KNG1 Products |
| Pathway Partner | BDKRB2 (Bradykinin Receptor B2) Downstream signaling target for pathway validation. |
View BDKRB2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Zymogen vs Active Form Discrimination | Separate lots of Prekallikrein (inactive) and Factor XIIa-activated KLKB1 (active) with verified catalytic activity status |
| Species Cross-reactivity (Cyno/Mouse/Rat) | Ortholog proteins available for Human, Cynomolgus, Mouse, and Rat with >95% purity; Sequence identity verified by mass spec |
| Selectivity vs Tissue Kallikreins (KLK Family) | Homolog panel (KLK1, KLK3, KLK7) for counter-screening; Strict sequence verification prevents cross-reactivity artifacts |
| Functional Activity Validation | Catalytic mutant (S195A) available as negative control for non-cleavable binding studies |
| Endotoxin Sensitivity | Endotoxin controlled <1 EU/μg; suitable for primary cell and in vivo assay applications |
| Benchmark Positive Controls | Sequence-verified Lanadelumab biosimilar antibody available for robust baseline establishment in selectivity and potency assays |
Live KLKB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active HAE Clinical Trials
- Diabetic Macular Edema (DME) Studies
- Latest Resistance & Mechanism Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for KLKB1 therapeutics is intensifying as the treatment paradigm for Hereditary Angioedema (HAE) shifts decisively from acute attack management to long-acting prophylaxis. With early generation monoclonal antibodies (e.g., Lanadelumab) validating the plasma kallikrein inhibition pathway, the current R&D focus has pivoted towards oral small molecules (Berotralstat, KVD900), next-generation prolonged half-life antibodies, and RNA-based therapeutics (siRNA/ASO) aimed at reducing patient burden. Furthermore, the landscape is expanding beyond HAE into Diabetic Macular Edema (DME) and vascular permeability disorders. As developers push for subcutaneous and oral modalities, extreme protease selectivity and prolonged formulation stability have become the definitive battlegrounds for best-in-class status. Emerging programs also target combination therapies with Bradykinin B2 receptor antagonists and novel siRNA approaches for sustained knockdown.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Takeda (Lanadelumab), Sanofi | HAE Prophylaxis | High-affinity binding to both zymogen and active forms; Species cross-reactivity panel (Human/Cyno/Mouse) |
| Small Molecule Inhibitor | BioCryst (Berotralstat), KalVista (KVD900), Pharvaris | HAE, DME | Enzymatic activity assays with active KLKB1; Selectivity screening vs KLK family |
| Substrate/Exosite Inhibitors | Academic/Early Biotech | Thrombosis, Inflammation | KNG1 substrate competition assays; Surface plasmon resonance (SPR) binding validation |
| Gene Therapy/siRNA | Early Pipeline | Chronic HAE | Lentivirus for stable overexpression cell lines; siRNA for knockdown efficiency validation |
Target Biology & Genetic Variations
KLKB1 encodes plasma prekallikrein, a serine protease composed of three Apple domains (Apple 1, Apple 2, Apple 3) critical for factor XII binding and activation. Key genetic variations include rs121964952 (uncertain significance in prekallikrein deficiency, PKKD), rs3733402, and rs4253257. Understanding these domains and mutations is essential for designing selective inhibitors and interpreting assay results.